AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24079838 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 100
Study 21298216 — intervention group
Group type: EXPERIMENTAL
Intervention: Project P.A.T.H.S. (experimental schools)
Number of subjects: 6000
Study 21298216 — intervention group
Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 6000
Study 19236467 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginsenoside-Rd 10 mg (group A)
Number of subjects: 199
Study 19236467 — intervention group
Group type: COMPARATOR
Intervention: Ginsenoside-Rd 20 mg (group C)
Number of subjects: 199
Study 19236467 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group B)
Number of subjects: 199
Study 19236467 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginsenoside-Rd (both doses)
Number of subjects: 199
Study 19236467 — intervention group
Group type: COMPARATOR
Intervention: All groups (including placebo)
Number of subjects: 199
Study 17958849 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenon E 15% Ointment
Number of subjects: 242
Study 17958849 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenon E 10% Cream
Number of subjects: 242
Study 17958849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study 15493847 — intervention group
Group type: EXPERIMENTAL
Intervention: Domestic octreotide injection (200 microg, intramuscular)
Number of subjects: 18
Study 15493847 — intervention group
Group type: EXPERIMENTAL
Intervention: Imported octreotide injection (200 microg, intramuscular)
Number of subjects: 18
Study 15493847 — intervention group
Group type: COMPARATOR
Intervention: Comparison of domestic and imported octreotide injections
Number of subjects: 18
Study 11434652 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic technique
Number of subjects: 0
Study 11434652 — intervention group
Group type: COMPARATOR
Intervention: Auscultation
Number of subjects: 0
Study 11434652 — intervention group
Group type: COMPARATOR
Intervention: Aspiration with inspection or pH determination
Number of subjects: 0
Study 11434652 — intervention group
Group type: COMPARATOR
Intervention: Traditional aspiration
Number of subjects: 0
Study 11434652 — intervention group
Group type: COMPARATOR
Intervention: Traditional feeding tube verification methods
Number of subjects: 0
Study 9577369 — intervention group
Group type: EXPERIMENTAL
Intervention: In situ nick translation (ISNT)
Number of subjects: 20
Study 9577369 — intervention group
Group type: EXPERIMENTAL
Intervention: TdT mediated dUTP‐biotin nick end labelling (TUNEL)
Number of subjects: 20
Study 9577369 — intervention group
Group type: COMPARATOR
Intervention: Both ISNT and TUNEL methods
Number of subjects: 20
Study 7944845 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy in hospitals with coronary revascularization services
Number of subjects: 438
Study 7944845 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy in small hospitals with coronary revascularization facilities
Number of subjects: 438
Study 7944845 — intervention group
Group type: COMPARATOR
Intervention: Thrombolytic therapy in hospitals without coronary revascularization services
Number of subjects: 438
Study 7944845 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy in smaller hospitals
Number of subjects: 438
Study 3308186 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01 mg daily
Number of subjects: 24
Study 3308186 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03 mg daily
Number of subjects: 24
Study 3308186 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.06 mg daily
Number of subjects: 24
Study 3308186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 28103427 — intervention group
Group type: EXPERIMENTAL
Intervention: LHTLH (normobaric hypoxia, Fi O2 14.2%)
Number of subjects: 30
Study 28103427 — intervention group
Group type: COMPARATOR
Intervention: LLTL (normoxia, no additional exercise)
Number of subjects: 30
Study 28103427 — intervention group
Group type: EXPERIMENTAL
Intervention: LHTL (normoxia, Fi O2 20.9%)
Number of subjects: 30
Study 28728077 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor control exercise
Number of subjects: 51
Study 28728077 — intervention group
Group type: COMPARATOR
Intervention: General exercises
Number of subjects: 51
Study 26158265 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 minutes per week of moderate-intensity aerobic exercise
Number of subjects: 101
Study 26158265 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 minutes per week of moderate-intensity aerobic exercise
Number of subjects: 101
Study 26158265 — intervention group
Group type: EXPERIMENTAL
Intervention: 225 minutes per week of moderate-intensity aerobic exercise
Number of subjects: 101
Study 26158265 — intervention group
Group type: COMPARATOR
Intervention: No-change control
Number of subjects: 101
Study 26158265 — intervention group
Group type: EXPERIMENTAL
Intervention: All exercise groups (per-protocol)
Number of subjects: 101
Study 26158265 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness response
Number of subjects: 101
Study 23827174 — intervention group
Group type: EXPERIMENTAL
Intervention: Transforaminal lumbar interbody fusion (TLIF)
Number of subjects: 40
Study 23827174 — intervention group
Group type: COMPARATOR
Intervention: Posterolateral lumbar fusion (PLF)
Number of subjects: 40
Study 20852871 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg once daily for 6 weeks
Number of subjects: 35
Study 20852871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 19014770 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (inhaled), administered twice daily
Number of subjects: 0
Study 19014770 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchodilator (albuterol)
Number of subjects: 0
Study 19014770 — intervention group
Group type: COMPARATOR
Intervention: Placebo (inhaled)
Number of subjects: 0
Study 16553653 — intervention group
Group type: EXPERIMENTAL
Intervention: STAN (automated fetal electrocardiography)
Number of subjects: 1483
Study 16553653 — intervention group
Group type: COMPARATOR
Intervention: CTG (conventional cardiotocography)
Number of subjects: 1483
Study 14567121 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17 beta‐estradiol gel (1.5 mg/day) plus nomegestrol acetate (5 mg/day)
Number of subjects: 106
Study 14567121 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral equine sulfoconjugated estrogen (0.625 mg/day) plus nomegestrol acetate (5 mg/day)
Number of subjects: 106
Study 14567121 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 106
Study 12932612 — intervention group
Group type: EXPERIMENTAL
Intervention: LVEF < 15%
Number of subjects: 7788
Study 12932612 — intervention group
Group type: EXPERIMENTAL
Intervention: LVEF 36% to 45%
Number of subjects: 7788
Study 12932612 — intervention group
Group type: COMPARATOR
Intervention: LVEF 46% to 55%
Number of subjects: 7788
Study 12932612 — intervention group
Group type: COMPARATOR
Intervention: LVEF > 55%
Number of subjects: 7788
Study 12932612 — intervention group
Group type: EXPERIMENTAL
Intervention: LVEF 16% to 25%
Number of subjects: 7788
Study 12932612 — intervention group
Group type: EXPERIMENTAL
Intervention: LVEF 26% to 35%
Number of subjects: 7788
Study 9477013 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling with systemic metronidazole plus amoxicillin and supragingival irrigation with chlorhexidine digluconate
Number of subjects: 48
Study 9477013 — intervention group
Group type: COMPARATOR
Intervention: Full mouth scaling alone
Number of subjects: 48
Study 7868462 — intervention group
Group type: EXPERIMENTAL
Intervention: Postexercise reduction of DLco
Number of subjects: 21
Study 7868462 — intervention group
Group type: EXPERIMENTAL
Intervention: Postexercise membrane diffusion capacity
Number of subjects: 21
Study 7868462 — intervention group
Group type: EXPERIMENTAL
Intervention: Postexercise pulmonary capillary blood volume
Number of subjects: 21
Study 7868462 — intervention group
Group type: EXPERIMENTAL
Intervention: Second bout of exercise
Number of subjects: 21
Study 7868462 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (iv)
Number of subjects: 21
Study 2681331 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) 3.2 mg per day
Number of subjects: 34
Study 2681331 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (PRED) 40 mg per day
Number of subjects: 34
Study 2681331 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) 2.0 mg per day
Number of subjects: 34
Study 2681331 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) ≥ 1.84 mg/day/70 kg
Number of subjects: 34
Study 2681331 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (PRED) ≥ 15 mg per day
Number of subjects: 34
Study 57959 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release decongestant combination
Number of subjects: 15
Study 57959 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine/chlorpheniramine
Number of subjects: 15
Study 57959 — intervention group
Group type: EXPERIMENTAL
Intervention: Full triple-drug capsule
Number of subjects: 15
Study 57959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31898550 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (two sessions or five sessions)
Number of subjects: 93
Study 31898550 — intervention group
Group type: COMPARATOR
Intervention: Group B (decoy option of seven sessions, two sessions or five sessions)
Number of subjects: 93
Study 28270380 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring system based on a digital health platform
Number of subjects: 110
Study 28270380 — intervention group
Group type: EXPERIMENTAL
Intervention: Vital signs (pulse rate, oxygen saturation, respiratory rate) acquired from a pulse oximeter
Number of subjects: 110
Study 28270380 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of vital signs with a robust algorithm based on machine learning
Number of subjects: 110
Study 26387946 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0
Study 26387946 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Number of subjects: 0
Study 26387946 — intervention group
Group type: EXPERIMENTAL
Intervention: NOTCH4 inhibition
Number of subjects: 0
Study 26387946 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of endocrine therapy with targeting JAG1-NOTCH4
Number of subjects: 0
Study 26387946 — intervention group
Group type: COMPARATOR
Intervention: High ALDH1
Number of subjects: 0
Study 26387946 — intervention group
Group type: COMPARATOR
Intervention: NOTCH4/HES/HEY gene signature
Number of subjects: 0
Study 23750462 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Analysis System of Psychotherapy (CBASP)
Number of subjects: 352
Study 23750462 — intervention group
Group type: EXPERIMENTAL
Intervention: CBASP plus antidepressant medication
Number of subjects: 352
Study 23750462 — intervention group
Group type: COMPARATOR
Intervention: Psychotherapy only (CBASP)
Number of subjects: 352
Study 21852067 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavefront-optimized PRK (Allegretto Wave Eye‐Q software version 2.020 default treatment)
Number of subjects: 132
Study 21852067 — intervention group
Group type: COMPARATOR
Intervention: Conventional PRK (Technolas 217z)
Number of subjects: 132
Study 21852067 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavefront-optimized PRK
Number of subjects: 132
Study 21852067 — intervention group
Group type: COMPARATOR
Intervention: Conventional PRK
Number of subjects: 132
Study 19151288 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive support ventilation (ASV)
Number of subjects: 128
Study 19151288 — intervention group
Group type: COMPARATOR
Intervention: Pressure-controlled/pressure-support ventilation (control)
Number of subjects: 128
Study 17920505 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of oral ibuprofen
Number of subjects: 159
Study 17920505 — intervention group
Group type: COMPARATOR
Intervention: 1 g of oral paracetamol
Number of subjects: 159
Study 15476632 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 0
Study 15476632 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 0
Study 11574180 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg 17beta‐estradiol/0.15 mg desogestrel (n=53)
Number of subjects: 125
Study 11574180 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg conjugated estrogens/0.15 mg norgestrel (n=36)
Number of subjects: 125
Study 11574180 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=36)
Number of subjects: 125
Study 9623427 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine 75 mg (group A; n = 15)
Number of subjects: 59
Study 9623427 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine 75 mg‐ketamine 0.3 mg kg‐1 (group B; n = 14)
Number of subjects: 59
Study 9623427 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine 75 mg‐ketamine 0.5 mg kg‐1 (group C; n = 5)
Number of subjects: 59
Study 9623427 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine 75 mg‐ketamine 0.67 mg kg‐1 (group D; n = 15)
Number of subjects: 59
Study 7836627 — intervention group
Group type: EXPERIMENTAL
Intervention: 142 mg Zn as Zn sulfate (ZnSO4) during Ca intakes of 230, 500 and 800 mg/day
Number of subjects: 3
Study 7836627 — intervention group
Group type: EXPERIMENTAL
Intervention: 142 mg Zn as Zn sulfate (ZnSO4)
Number of subjects: 3
Study 2905806 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg lormetazepam
Number of subjects: 40
Study 2905806 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg lormetazepam
Number of subjects: 40
Study 2905806 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg flunitrazepam
Number of subjects: 40
Study 2905806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31795895 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment in MR CLEAN trial
Number of subjects: 1156
Study 31795895 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment in IMS III trial
Number of subjects: 1156
Study 31795895 — intervention group
Group type: EXPERIMENTAL
Intervention: NIHSS at 24 hours and 5 to 7 days
Number of subjects: 1156
Study 31795895 — intervention group
Group type: EXPERIMENTAL
Intervention: NIHSS as a primary outcome measure
Number of subjects: 1156
Study 30209561 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue-strengthening exercises (TSE) at 100% 1RM
Number of subjects: 60
Study 30209561 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue-strengthening exercises (TSE) at 80% 1RM
Number of subjects: 60
Study 30209561 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue-strengthening exercises (TSE) at 60% 1RM
Number of subjects: 60
Study 30209561 — intervention group
Group type: COMPARATOR
Intervention: Control group performing lip-strengthening exercises (CG)
Number of subjects: 60
Study 29209514 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (6 capsules of 1g daily, totaling 3.6g LCn-3PUFA)
Number of subjects: 13
Study 29209514 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (placebo)
Number of subjects: 13
Study 24889819 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic interventions using a short double-balloon endoscope
Number of subjects: 110
Study 23104014 — intervention group
Group type: EXPERIMENTAL
Intervention: Music tailored to overcompensate for hearing loss
Number of subjects: 0
Study 23104014 — intervention group
Group type: COMPARATOR
Intervention: Unmodified music (active control group)
Number of subjects: 0
Study 23104014 — intervention group
Group type: COMPARATOR
Intervention: Music spectrally tailored to compensate for hearing loss
Number of subjects: 0
Study 20851565 — intervention group
Group type: EXPERIMENTAL
Intervention: Directed air flow system
Number of subjects: 36
Study 20851565 — intervention group
Group type: COMPARATOR
Intervention: Directed air flow system (turned off)
Number of subjects: 36
Study 20851565 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 20120795 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplementation
Number of subjects: 12
Study 16884779 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cyclosporine 0.05% 4 times a day
Number of subjects: 52
Study 16884779 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cyclosporine 0.05% with pulsed prednisolone acetate 1% dosing
Number of subjects: 52
Study 16884779 — intervention group
Group type: COMPARATOR
Intervention: Historical control subjects using topical steroids
Number of subjects: 52
Study 15255128 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% HES + 4% albumin (group 1)
Number of subjects: 29
Study 15255128 — intervention group
Group type: EXPERIMENTAL
Intervention: FFP (group 2)
Number of subjects: 29
Study 15255128 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% Varihes/Isohes (group 3)
Number of subjects: 29
Study 15255128 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% albumin (group 4)
Number of subjects: 29
Study 11725240 — intervention group
Group type: EXPERIMENTAL
Intervention: Periradicular infiltration with methylprednisolone-bupivacaine
Number of subjects: 160
Study 11725240 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 160
Study 10322817 — intervention group
Group type: EXPERIMENTAL
Intervention: Huoxue Tablet
Number of subjects: 75
Study 10322817 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite Danshen tablet
Number of subjects: 75
Study 10322817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 8110625 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide (group D): day 0, 3.6 g by intravenous infusion in 12 hours; days +1 to +6, 800 mg tid intravenously; days +7 to +10/+12, 400 mg tid intramuscularly
Number of subjects: 137
Study 8110625 — intervention group
Group type: COMPARATOR
Intervention: Heparin (group H): day 0, 1000 IU/hour infused over 12 hours; days +1 to +10/+12, 5000 IU tid subcutaneously
Number of subjects: 137
Study 8110625 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide (group D)
Number of subjects: 137
Study 8110625 — intervention group
Group type: COMPARATOR
Intervention: Heparin (group H)
Number of subjects: 137
Study 3314717 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% to 3% topical minoxidil solution
Number of subjects: 72
Study 3314717 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% topical minoxidil solution
Number of subjects: 72
Study 31556447 — intervention group
Group type: EXPERIMENTAL
Intervention: Benefit-Finding Intervention (BFT)
Number of subjects: 96
Study 31556447 — intervention group
Group type: COMPARATOR
Intervention: Simplified Psychoeducation (SIM-PE)
Number of subjects: 96
Study 31556447 — intervention group
Group type: COMPARATOR
Intervention: Standard Psychoeducation (STD-PE)
Number of subjects: 96
Study 30481185 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological intervention
Number of subjects: 31
Study 30481185 — intervention group
Group type: COMPARATOR
Intervention: Usual advocacy
Number of subjects: 31
Study 27974311 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive medical nutrition therapy with energy intakes at nationally recommended amounts
Number of subjects: 78
Study 27974311 — intervention group
Group type: COMPARATOR
Intervention: Standard nutrition support care providing energy at 55% of recommended concentrations
Number of subjects: 78
Study 27974311 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher early energy intake (≥8 days)
Number of subjects: 78
Study 27974311 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher late energy intake (≥8 days)
Number of subjects: 78
Study 27974311 — intervention group
Group type: EXPERIMENTAL
Intervention: Early protein exposure (grams per kilogram)
Number of subjects: 78
Study 27974311 — intervention group
Group type: EXPERIMENTAL
Intervention: Late protein exposure (grams per kilogram)
Number of subjects: 78
Study 26654448 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous wound infiltration plus patient-controlled analgesia (CWI+PCA)
Number of subjects: 102
Study 26654448 — intervention group
Group type: COMPARATOR
Intervention: Continuous (thoracic) epidural analgesia (CEA)
Number of subjects: 102
Study 26654448 — intervention group
Group type: EXPERIMENTAL
Intervention: CWI+PCA
Number of subjects: 102
Study 23923976 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging group (n=211)
Number of subjects: 431
Study 23923976 — intervention group
Group type: COMPARATOR
Intervention: Paper-and-pencil group (n=220)
Number of subjects: 431
Study 21072684 — intervention group
Group type: EXPERIMENTAL
Intervention: IMSI (Intracytoplasmic Morphologically Selected Sperm Injection)
Number of subjects: 0
Study 21072684 — intervention group
Group type: COMPARATOR
Intervention: Standard ICSI
Number of subjects: 0
Study 17487257 — intervention group
Group type: EXPERIMENTAL
Intervention: NT‐proBNP measured at baseline, 72 h, and 30 days
Number of subjects: 304
Study 17487257 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta NT‐proBNP (72 h value - baseline NT‐proBNP)
Number of subjects: 304
Study 17487257 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline NT‐proBNP
Number of subjects: 304
Study 17487257 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta NT‐proBNP
Number of subjects: 304
Study 17487257 — intervention group
Group type: EXPERIMENTAL
Intervention: c‐statistic for baseline, 72 to 96 h, and Delta NT‐proBNP
Number of subjects: 304
Study 15136972 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (200 mg/kg) after treatment with ramipril (5 mg/day)
Number of subjects: 0
Study 15136972 — intervention group
Group type: COMPARATOR
Intervention: L-arginine (200 mg/kg) after treatment with losartan (50 mg/day)
Number of subjects: 0
Study 15136972 — intervention group
Group type: COMPARATOR
Intervention: L-arginine alone
Number of subjects: 0
Study 15136972 — intervention group
Group type: COMPARATOR
Intervention: L-arginine after treatment with ramipril or losartan
Number of subjects: 0
Study 11591569 — intervention group
Group type: EXPERIMENTAL
Intervention: ipratropium bromide HFA, 42 microg
Number of subjects: 507
Study 11591569 — intervention group
Group type: EXPERIMENTAL
Intervention: ipratropium bromide HFA, 84 microg
Number of subjects: 507
Study 11591569 — intervention group
Group type: EXPERIMENTAL
Intervention: ipratropium bromide inhalation aerosol, 42 microg
Number of subjects: 507
Study 11591569 — intervention group
Group type: COMPARATOR
Intervention: HFA placebo
Number of subjects: 507
Study 11591569 — intervention group
Group type: COMPARATOR
Intervention: CFC placebo
Number of subjects: 507